

In salmon farming Canada produced 21,000 tons and a revenue of \$150 million in 1991. This makes Canada the third largest salmon farming nation in the world. Other species like Rainbow trout are being successfully developed in Ontario⁵². The fact that Spain is one of the largest fish and seafood consumers in the world, and the first in Europe makes it worthwhile to explore areas of collaboration in aquaculture between the two countries. Some products and areas of development include, vaccines for fish grown by aquaculture, fish health monitoring systems, diagnostic tests for the detection of fish pathogens, etc.

2. BIOPHARMACEUTICALS

The Canadian pharmaceutical manufacturers see themselves as the kind of industry that the country needs for the future; technology and research based, with large value added products. It is after telecommunications, and aerospace industries, the sector spending the greatest percent of sales in R & D (8,8 %)⁵³. Also, Canada is one of the ten largest pharmaceutical markets with sales of \$4 billion of prescription drugs a year⁵⁴. When the National Biotechnology Strategy was developed in 1983 Canada had a minor presence in the international pharmaceutical industry. Through the 1980s, this sector has emerged as a strong and dynamic one within the biotech industry. There are two reason for this upsurge of biopharmaceuticals in Canada. The strength of R & D in health care, and the dramatic increase in R & D investment.

Much of the Canadian pharmaceutical industry (about 85 %) is multinational. According to the third annual report of the Patented Medicine Prices Review Board, R & D investment in 1990 by patent-holding drug companies totalled \$281.3 million or 8.8 % of sales. That is three times the level of 1987. Ontario, and particularly the Toronto area, accounts for 50 % of the manufacturing firms of the pharmaceutical industry, followed by the province of Quebec with 34 %.

In 1991 there were in Canada nearly 10 medium sized firms in the diagnostic kits or biopharmaceuticals capable of having a good level of R & D. These companies as indicated earlier have 50-100 employees. Many Canadian firms have commercial kits on the market.

Clinical diagnostics is the fastest growing sub-sector of this industry with a sales volume over \$600 million extrapolatable to \$1 billion by the year 2000. Canadian owned firms amount to 87 and sold only \$100 million in 1991.

The industry is involved in a wide spectrum of R & D activities which include: anti-inflammatory drug development, antibody/radioisotope